Short answer
Zenas BioPharma, Inc. (ZBIO) filed an 8-K current report with the SEC on May 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Quarterly financial results released for period ended March 31, 2026.
Zenas BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly financial results released for period ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial details
- Disclosure furnished under Regulation FD, not filed under Exchange Act Section 18 liability rules
Item 5.02 · Departure/Election of Directors or Officers
- Tomas Kiselak’s board term ended May 11, 2026, following his decision not to seek re-election
- Board size reduced by one, potentially affecting governance capacity and committee composition
Item 5.07 · Submission of Matters to a Vote of Security Holders
- James Boylan and Patrick Enright elected as Class II directors through the 2029 annual meeting
- Director votes included 4,458,184 broker non-votes, reflecting shares not counted on uncontested elections
- Ernst & Young LLP ratified as independent auditor for fiscal year ending December 31, 2026
- Auditor appointment received 52,654,975 for votes versus 7,650 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zenas BioPharma, Inc. 8-K filings
Get the next ZBIO 8-K as it lands
Follow ZBIO for push alerts, or ask the research agent what this filing means.